Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Addis

Vascular Surgery Springfield, NJ Medical Doctor

NPI 1275525743 CMS profile 284483

649 Morris Ave, Springfield, NJ 07081

Open in the dashboard

General payments

$15,800

322 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Addis of Springfield, NJ is reported in the CMS Open Payments database as having received $15,800 across 322 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,801 35
2024 General $3,003 47
2023 General $2,104 58
2022 General $3,572 74
2021 General $1,754 51
2020 General $720 24
2019 General $2,845 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Addis
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Michael Addis were reported at $1,801. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Michael Addis Vascular Surgery median Middle half National median
2019 $2,845 $796 $226–$2,363 $163
2020 $720 $348 $118–$1,110 $114
2021 $1,754 $471 $158–$1,421 $132
2022 $3,572 $725 $222–$2,183 $149
2023 $2,104 $836 $257–$2,440 $160
2024 $3,003 $909 $252–$2,619 $164
2025 $1,801 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,985 113 payments
  2. Silk Road Medical, Inc. $2,130 27 payments
  3. W. L. Gore & Associates, Inc. $1,860 54 payments
  4. Inari Medical, Inc. $1,378 18 payments
  5. Penumbra, Inc. $1,321 12 payments
  6. Endologix, Inc. $1,122 7 payments
  7. Bolton Medical Inc $634 5 payments
  8. Cardiovascular Systems Inc. $432 4 payments
  9. Tactile Systems Technology Inc $409 8 payments
  10. Medtronic Vascular, Inc. $375 14 payments
  11. Other $3,154 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,021 318 payments
  2. Travel and Lodging $778 4 payments
Products named General payments · program years 2019–2025
  1. ENROUTE 0.014 Guidewire $1,347 16 payments
  2. ENROUTE Transcarotid Stent System $1,347 16 payments
  3. ENROUTE Transcarotid Neuroprotection System $1,347 16 payments
  4. ENHANCE Transcarotid Peripheral Access Kit $1,347 16 payments
  5. FLOWTRIEVER CATHETER, S $1,221 17 payments
  6. HawkOne $1,203 41 payments
  7. CT THROMBECTOMY SYSTEM KIT $1,032 13 payments
  8. GORE VIABAHN VBX Balloon Expandable Endo $957 10 payments
  9. Alto Abdominal Stent Graft System $853 5 payments
  10. ENROUTE Transcarotid Stent $783 11 payments
  11. Other $11,898 273 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

128

Median for Vascular Surgery: 122

Drug cost

$25,764

Median for Vascular Surgery: $14,135

Branded share of claims

75.8%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 37 $24,520
Clopidogrel Clopidogrel Bisulfate Brand 45 $579
Cilostazol Generic 31 $470
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 15 $196

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 110 billing codes

Paid by Medicare

$267,602

Medicare's payments for the services billed

Medicare patients

616

Average age 75

Services billed

1,497

308 women, 308 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 55%
Diabetes 53%
Arthritis 51%
Chronic kidney disease 49%
Heart failure 33%
Atrial fibrillation 32%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

322 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record